Introduction
============

Epidemiological data show that 14.1 million new cancer cases and 8.2 million cancer deaths occurred in 2012 worldwide;[@b1-cmar-10-1471] in other words, cancer is a leading cause of death in both more and less economically developed countries.[@b2-cmar-10-1471] Although considerable improvements have been made with respect to diagnostic capabilities and therapeutic methods, patients still face poor prognosis, especially in the advanced stages of the disease.[@b3-cmar-10-1471] A lack of biomarkers for early diagnosis has limited the efficacy of current therapies for patients with solid tumors. Therefore, identification of prognostic biomarkers for human solid tumors and elucidation of their molecular mechanisms are urgent priorities for improving standard diagnosis, therapy, and prognosis.

Recently, the role of special AT-rich sequence-binding protein 1 (SATB1) in tumorigenesis and tumor progression has become a focus of research. SATB1 is a cell type-specific nuclear matrix-associated protein that is predominantly expressed in thymocytes.[@b4-cmar-10-1471] SATB1 serves as a gene regulator and a genome organizer, as it can form a characteristic "cage-like" network that surrounds the heterochromatin to fold chromatin into complex higher order structures. It can also provide a nuclear platform that recruits chromatin-modifying enzymes and chromatin remodeling.[@b5-cmar-10-1471],[@b6-cmar-10-1471] SATB1 has been reported to influence the expression of hundreds of genes, including some involved in the pathogenesis of human cancers.[@b7-cmar-10-1471] These findings suggest that SATB1 may be involved in the carcinogenesis and/or progression of human malignancies. Many retrospective studies have evaluated whether SATB1 overexpression may be a prognostic factor for survival in patients with diverse types of solid tumors, including gastric cancer,[@b8-cmar-10-1471]--[@b10-cmar-10-1471] breast cancer,[@b11-cmar-10-1471],[@b12-cmar-10-1471] glioma,[@b13-cmar-10-1471],[@b14-cmar-10-1471] epithelial ovarian cancer,[@b15-cmar-10-1471] colorectal cancer,[@b16-cmar-10-1471]--[@b20-cmar-10-1471] astrocytoma,[@b21-cmar-10-1471] pancreatic cancer,[@b22-cmar-10-1471] endometrial cancer,[@b23-cmar-10-1471] bladder cancer,[@b24-cmar-10-1471] and esophageal squamous cell carcinoma.[@b25-cmar-10-1471] In addition, several studies found that the expression of SATB1 was not significantly associated with prognosis.[@b19-cmar-10-1471],[@b21-cmar-10-1471] Overall, the reported results are inconclusive, and no consensus has been reached. It is necessary to establish whether SATB1 expression is a prognostic marker for human solid tumors. In this study, we conducted a meta-analysis to evaluate the prognostic role of SATB1 expression in patients with solid tumors.

Methods
=======

Literature search strategy
--------------------------

An electronic search of EMBASE, PubMed, and Web of Science was carried out to identify studies evaluating SATB1 expression and clinical outcome in solid tumors prior to April 2017. The search terms included ''special AT-rich sequence-binding protein 1'' or ''SATB1'' and ''cancer'' or ''tumor'' or ''neoplasms'' or ''survival'' or ''prognosis''. Only studies of solid tumors in humans were considered. A total of 982 studies were identified. The reference lists of studies were scanned for relevant reports, and further analysis was performed on articles of possible interest. Cohen's kappa coefficient was used to determine inter-reviewer agreement. We would go all the way to reach a consensus if there was any disagreement between assessors.

Study selection
---------------

To be eligible for inclusion in this meta-analysis, a study had to meet the following criteria: 1) measure the expression of SATB1 with immunohistochemistry in the primary cancer tissue; 2) investigate the association between SATB1 and patients' prognosis (overall survival \[OS\]); 3) have a follow-up period of no less than 3 years; 4) be published in the English language; and 5) be the most complete report or the most recent one, when the same author(s) published more than one on the same patient population. All candidate manuscripts were carefully read by two independent authors (Wang and Huang). In order to obtain a consensus, these two authors resolved any disagreements or conflicting results.

Data collection process and quality assessment
----------------------------------------------

Two investigators (Wang and Liu) aimed to assess studies that included independently patient number, sex, median age, country, cancer type, follow-up duration, references, cutoff value for SATB1 positivity, cutoff definition, and hazard ratios (HRs) for OS with corresponding 95% confidence intervals (CIs). The OS data were acquired from tables or Kaplan-Meier curves that contained negative and positive groups for SATB1. All studies included in the meta-analysis were entire cohort studies. Each publication was scored based on the Newcastle--Ottawa scale (NOS) to identify high-quality studies.[@b26-cmar-10-1471] The score ranges from 0 to 9; a study with a score ≥6 was considered to be methodologically sound. A consensus NOS score was reached for each publication by discussion.

Statistical analysis
--------------------

Data were acquired from the original articles and analyzed using the RevMan 5.3 software. The Mantel-Haenszel random-effects model was used for the weighted and pooled HR estimates, while Cochran's *Q* and *I*^2^ were used for the heterogeneity statistics.[@b27-cmar-10-1471],[@b28-cmar-10-1471] As recommended by the Cochrane Handbook for Systematic Reviews of Interventions, differences appearing in the subgroups were assessed. A difference was considered statistically significant if two-sided *P*\<0.05. Publication bias was estimated qualitatively using funnel plots with the standard error and evaluated by Begg's and Egger's tests.[@b29-cmar-10-1471]

Results
=======

Search results and study characteristics
----------------------------------------

Seventeen studies involving a total of 3144 patients were used for the meta-analysis ([Figure 1](#f1-cmar-10-1471){ref-type="fig"}). The included studies are summarized in [Table 1](#t1-cmar-10-1471){ref-type="table"}. Five studies evaluated colorectal cancer,[@b16-cmar-10-1471]--[@b20-cmar-10-1471] three studies evaluated gastric cancer,[@b8-cmar-10-1471]--[@b10-cmar-10-1471] two studies focused on breast cancer[@b11-cmar-10-1471],[@b12-cmar-10-1471] and glioma,[@b13-cmar-10-1471],[@b14-cmar-10-1471] and one each evaluated epithelial ovarian cancer,[@b15-cmar-10-1471] astrocytoma,[@b21-cmar-10-1471] pancreatic cancer,[@b22-cmar-10-1471] endometrial cancer,[@b23-cmar-10-1471] bladder cancer,[@b24-cmar-10-1471] and esophageal squamous cell carcinoma.[@b25-cmar-10-1471] The studies were performed in five countries (People's Republic of China, Germany, Poland, Australia, and Sweden) and published prior to April 2017.

Association of SATB1 with OS
----------------------------

There were 14 studies that reported OS data with multivariate analysis. The relevant results showed that SATB1 overexpression in human tumor tissues was associated with a decrease in survival among solid tumor patients (HR = 1.82; 95% CI 1.59--2.08, *P* \< 0.00001) ([Figure 2](#f2-cmar-10-1471){ref-type="fig"}). There was no evidence of heterogeneity among the 14 studies mentioned (*P* = 0.81, *I*^2^ = 0 %). Pooled HRs for OS according to subgroup analysis of the included studies are shown in [Table 2](#t2-cmar-10-1471){ref-type="table"}. We further performed a subgroup analysis to assess OS data for different types of cancer using univariate analysis. Three reports provided OS data for gastric cancer and colorectal cancer, and two for glioma. A stratified analysis on solid tumor type showed that SATB1 overexpression was connected with negative clinical outcomes in gastric cancer (HR = 1.88; 95% CI 1.41--2.52, *P* \< 0.0001) ([Figure 3A](#f3-cmar-10-1471){ref-type="fig"}), colorectal cancer (HR = 1.58; 95% CI 1.25--2.00, *P* \< 0.0001) ([Figure 3B](#f3-cmar-10-1471){ref-type="fig"}), and glioma (HR = 2.58; 95% CI 1.74--3.81, *P* \< 0.00001) ([Figure 3C](#f3-cmar-10-1471){ref-type="fig"}). There were 10 studies reporting OS data with univariate analysis. Relevant results showed that SATB1 overexpression in human tumor tissues was related to a decrease in survival among solid tumor patients (HR = 1.96; 95% CI 1.65--2.34, *P* \< 0.00001) ([Figure 4](#f4-cmar-10-1471){ref-type="fig"}). Among the 14 studies involved, there was no significant heterogeneity (*P* = 0.91, *I*^2^ = 0%). We further conducted a subgroup analysis to assess OS data for different types of cancer with multivariate analysis. Three reports provided OS data for colorectal cancer and two studies for glioma. A stratified analysis of solid tumor type found that SATB1 overexpression was connected with negative clinical outcomes in colorectal cancer (HR = 2.04; 95% CI 1.44--2.89, *P* \< 0.0001) ([Figure 5A](#f5-cmar-10-1471){ref-type="fig"}), and glioma (HR = 2.15; 95% CI 1.47--3.15, *P* \< 0.00001) ([Figure 5B](#f5-cmar-10-1471){ref-type="fig"}).

Publication bias
----------------

The funnel plots showed no evidence of publication bias in the studies of either outcome. No evidence for significant publication bias was found for OS with multivariate analysis ([Figure 6A](#f6-cmar-10-1471){ref-type="fig"}) or univariate analysis ([Figure 6B](#f6-cmar-10-1471){ref-type="fig"}).

Discussion
==========

Over the past several decades, much research has focused on identifying novel prognostic markers in order to advance therapy and outcomes by informing clinical decision making. The prognostic significance of SATB1 expression has been investigated in a wide range of cancers. Here, we aimed to summarize and evaluate the findings of published studies and extract valuable information that can be used in clinical decision-making regarding human solid tumors.

This meta-analysis was the first systematic review to investigate in depth the relationship between SATB1 overexpression and OS of patients with solid tumors. Survival data for 3144 solid tumor patients in 17 different studies were systematically analyzed. The meta-analysis indicated that the overexpression of SATB1 could be used as a biomarker of poor prognosis in human with solid tumors, with similar OS results given by the multivariate and the univariate analysis. Regarding solid tumors of different tissues, high SATB1 expression was relevant to poor OS in gastric cancer, colorectal carcinoma, and glioma. Similarly, increased SATB1 expression was associated with poor survival in solid tumors. Further studies are required to verify the potential mechanism and impact of SATB1 in the pathogenesis of human solid tumors, in addition to its prognostic value.

There are several crucial implications of this meta-analysis. First, SATB1 expression is associated with adverse outcomes in various human solid tumors, indicating that SATB1 may be of use as a new therapeutic target. Second, in a subgroup of tumors, tumor tissues with high SATB1 expression were shown to have worse OS, including gastric cancer, colorectal carcinoma, and glioma. Overall, this study highlights SATB1 as a valuable prognostic biomarker with potential clinical applications.

However, this meta-analysis had some deficiencies and limitations. First, there was a risk of publication bias, as some studies with small sample sizes or negative results may not have been published. Second, there may be inconsistent data in the included reports, as they used different cutoff values and analysis methods for evaluating SATB1 overexpression. Finally, there may be a certain publication bias within some of the included studies, as any negative results are less likely to have been reported.

Conclusion
==========

In general, this meta-analysis makes it clear that SATB1 overexpression is related to poor OS in the case of most human solid tumors. It also suggests that SATB1 is both a promising prognostic indicator and a potential therapeutic target for human solid tumors.
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![Meta-analysis of the association between SATB1 and OS (multivariate analysis) in patients with solid tumors.\
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![Subgroup analysis of OS (multivariate analysis) by SATB1 expression in various tumor types. (**A**) Gastric cancer; (**B**) colorectal cancer; and (**C**) glioma.\
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![Meta-analysis of the association between SATB1 and OS (univariate analysis) in patients with solid tumors.\
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![Subgroup analysis of OS (univariate analysis) by SATB1 expression in various tumor types. (**A**) Colorectal cancer and (**B**) glioma.\
**Abbreviations:** CI, confidence interval; HR, hazard ratio; IV, inverse variance; OS, overall survival; SATB1, special AT-rich sequence-binding protein 1; SE, standard error.](cmar-10-1471Fig5){#f5-cmar-10-1471}

![Begg's funnel plot estimation of the publication bias of the included literature for OS with multivariate analysis (**A**) and univariate analysis (**B**).\
**Abbreviation:** OS, overall survival.](cmar-10-1471Fig6){#f6-cmar-10-1471}

###### 

Characteristics of the included studies

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  References                            Country                      Cancer type          Case no.   Male/female   Age (years)                       Detection method (cutoff)   Increased SATB1 (%)   Follow-up (months)   Survival analysis   HR (95% CI)          NOS (scores)
  ------------------------------------- ---------------------------- -------------------- ---------- ------------- --------------------------------- --------------------------- --------------------- -------------------- ------------------- -------------------- --------------
  Cheng et al[@b8-cmar-10-1471]         People's Republic of China   Gastric cancer       102        63/39         Mean 62.0                         IHC (score ≥3)              49 (48.0%)            87                   OS (M)              1.79 (1.08--2.97)    9

  Lu et al[@b9-cmar-10-1471]            People's Republic of China   Gastric cancer       118        78/40         Mean 60.3                         IHC (score ≥2)              56 (47.5%)            91                   OS (M)              1.71 (1.08--2.71)    9

  Chu et al[@b13-cmar-10-1471]          People's Republic of China   Glioma               70         54/16         Mean 45.0                         IHC (score ≥2)              44 (62.9%)            86                   OS (U)\             2.22 (1.14--4.34)\   8
                                                                                                                                                                                                                            OS (M)              2.22 (1.23--4.00)    

  Nodin et al[@b15-cmar-10-1471]        Sweden                       Ovarian cancer       105        NR            NR                                NR                          18 (17.14%)           60                   OS (M)              2.06 (1.11--3.81)    6

  Nodin et al[@b16-cmar-10-1471]        Sweden                       Colorectal cancer    529        246/283       361/168 (\<75 years/\>75 years)   IHC (score \>3)             96 (18.1%)            120                  OS (M)              2.05 (1.09--3.88)    8

  Chu et al[@b21-cmar-10-1471]          People's Republic of China   Astrocytoma          113        68/45         Mean 45.0                         IHC (score ≥2)              71 (62.8%)            60                   OS (U)\             2.34 (0.77--7.09)\   8
                                                                                                                                                                                                                            OS (M)              2.17 (0.75--6.28)    

  Han et al[@b14-cmar-10-1471]          People's Republic of China   Glioma               79         53/26         Mean 45.5                         IHC (score \>4)             45 (57.0%)            36                   OS (U)\             2.12 (1.33--3.38)\   8
                                                                                                                                                                                                                            OS (M)              2.90 (1.72--4.88)    

  Elebro et al[@b22-cmar-10-1471]       Sweden                       Pancreatic cancer    106        57/49         Mean 67.0                         NR                          21 (19.8%)            60                   OS (U)\             2.11 (1.25--3.56)\   8
                                                                                                                                                                                                                            OS (M)              1.79 (1.05--3.05)    

  Hedner et al[@b10-cmar-10-1471]       Sweden                       Gastric cancer       170        129/41        NR                                IHC (staining ≥2%)          53 (31.2%)            96                   OS (U)\             1.74 (1.04--2.90)\   9
                                                                                                                                                                                                                            OS (M)              2.30 (1.32--4.01)    

  Al-Sohaily et al[@b20-cmar-10-1471]   Australia                    Colorectal cancer    352        191/152       197/145 (\<70 years/\>70 years)   IHC (staining ≥5%)          266 (78.0%)           120                  OS (U)              2.48 (1.31--4.69)    8

  Niu et al[@b17-cmar-10-1471]          People's Republic of China   Colorectal cancer    131        78/53         59/72 (\<60 years/≥60 years)      IHC (score ≥3)              64 (48.5%)            72                   OS (U)\             2.33 (1.36--3.99)\   9
                                                                                                                                                                                                                            OS (M)              1.77 (1.03--3.04)    

  Zhang et al[@b18-cmar-10-1471]        People's Republic of China   Colorectal cancer    520        311/209       254/266 (\<60 years/≥60 years)    TMA (strongly staining)     205 (39.4%)           120                  OS (M)              1.45 (1.09--1.93)    9

  Zhang et al[@b23-cmar-10-1471]        People's Republic of China   Endometrial cancer   172        NR            112/60 (\<55 years/≥55 years)     NR                          78                    84                   OS (M)              2.93 (1.07--8.02)    7

  Kowalczyk et al[@b19-cmar-10-1471]    Poland                       Colorectal cancer    102        54/48         Mean 57.3                         IHC (score \>4)             41                    60                   OS (U)              1.39 (0.73--2.63)    8

  Liu et al[@b12-cmar-10-1471]          People's Republic of China   Breast cancer        169        0/169         Mean 53.6                         IHC (score ≥3)              92                    120                  OS (U)              2.41 (1.20--4.84)    7

  Wan et al[@b24-cmar-10-1471]          People's Republic of China   Bladder cancer       126        83/43         Mean 62.5                         IHC (score ≥3)              71                    72                   OS (M)              1.82 (1.19--2.78)    9

  Cong et al[@b25-cmar-10-1471]         People's Republic of China   Esophageal cancer    180        129/51        Mean 61.0                         IHC (score ≥4.5)            87                    120                  OS (U)\             1.62 (1.11--2.37)\   9
                                                                                                                                                                                                                            OS (M)              1.58 (1.08--2.31)    
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** CI, confidence interval; HR, hazard ratio; IHC, immunohistochemistry; M, multivariate analysis; no., number; NOS, Newcastle--Ottawa Scale; NR, not reported; OS, overall survival; SATB1, special AT-rich sequence-binding protein 1; U, univariate analysis.

###### 

Pooled HR for OS according to subgroup analysis

  References Analysis type    No. of studies   No. of patients   Fixed-effect model   Heterogeneity       
  --------------------------- ---------------- ----------------- -------------------- --------------- --- ------
   Multivariate               10               1473              1.82 (1.59--2.08)    \<0.00001       0   0.81
   Univariate                 14               2521              1.96 (1.65--2.34)    \<0.00001       0   0.91
  Tumor type (univariate)                                                                                 
   Colorectal cancer          3                585               2.04 (1.44--2.89)    \<0.0001        0   0.38
   Glioma                     2                149               2.15 (1.47--3.15)    \<0.0001        0   0.91
   Others                     5                793               1.86 (1.46--2.36)    \<0.00001       0   0.83
  Tumor type (multivariate)                                                                               
   Colorectal cancer          3                1180              1.58 (1.25--2.00)    \<0.0001        0   0.56
   Gastric cancer             3                390               1.88 (1.41--2.52)    \<0.0001        0   0.70
   Glioma                     2                149               2.58 (1.74--3.81)    \<0.00001       0   0.51
   Others                     6                802               1.81 (1.45--2.26)    \<0.00001       0   0.90
  Ethnicity (univariate)                                                                                  
   Asian                      6                742               2.01 (1.61--2.51)    \<0.00001       0   0.85
   Caucasian                  4                731               1.89 (1.42--2.52)    \<0.0001        0   0.61
  Ethnicity (multivariate)                                                                                
   Asian                      11               2140              1.78 (1.54--2.06)    \<0.00001       0   0.81
   Caucasian                  3                381               2.03 (1.46--2.82)    \<0.0001        0   0.82

**Abbreviations:** CI, confidence interval; HR, hazard ratio; No., number.

[^1]: These authors contributed equally to this work
